NEJM This Week — June 4, 2026

This week's issue: 3 randomized trials summarized in PICO with the clinical bottom line, plus one review and one teaching case. One original article (ASCERTAIN-V) was a single-arm, non-randomized study and is noted at the end rather than summarized as a trial.

CardiologyCHAMPION-AF · RCTHigh yield · IM

Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation

Population: 3,000 adults with AF at increased stroke risk (CHA₂DS₂-VASc ≥2 men / ≥3 women) who were suitable anticoagulation candidates. Excluded: MI, stroke/TIA, or major bleed within 30 days. Mean age 72; mean CHA₂DS₂-VASc 3.5.
Intervention: Percutaneous LAAC with the Watchman FLX device.
Comparison: Guideline-directed NOAC therapy.
Outcome: Primary composite (CV death, stroke, systemic embolism) at 3 yr: 5.7% vs 4.8%, difference 0.9 pts (95% CI −0.8 to 2.6); P<0.001 for noninferiority (margin 4.8 pts). Non–procedure-related bleeding: 10.9% vs 19.0% (HR 0.55; P<0.001 for superiority).

Clinical takeaway. In AF patients who are good anticoagulation candidates, LAAC was noninferior to NOACs for thromboembolic events and caused less non–procedure-related bleeding at 3 years. The accompanying editorial urges caution: observed event rates were less than half those assumed (making noninferiority easier to meet), the bleeding benefit is hard to attribute given concomitant antiplatelet use and apixaban's already-low bleeding risk, the trial was industry-funded, and the smaller CLOSURE-AF trial did not show noninferiority. Reasonable to consider case-by-case via shared decision-making — not a wholesale NOAC replacement.

NephrologyFIND-CKD · RCTHigh yield · IM

Finerenone in Persons with Chronic Kidney Disease without Diabetes

Population: 1,584 adults without diabetes with CKD (eGFR 25–<90) and albuminuria (UACR 200–3500) on a stable ACEi/ARB. Excluded: diabetes/HbA1c ≥6.5%, need for steroidal MRA, polycystic kidney disease, lupus nephritis, ANCA vasculitis; required K⁺ ≤4.8.
Intervention: Finerenone 10–20 mg daily (nonsteroidal MRA).
Comparison: Placebo.
Outcome: Total eGFR slope to month 32: −3.3 vs −4.0 mL/min/1.73m²/yr (difference 0.7; 95% CI 0.3 to 1.1; P<0.001). Composite kidney/CV events: HR 0.77 (0.60–0.99; P=0.04). Hyperkalemia 17.0% vs 13.3% (serious <1%).

Clinical takeaway. Finerenone slowed eGFR decline and reduced a composite kidney/CV outcome in non-diabetic CKD already treated with RAS blockade — extending the benefit previously shown only in diabetic CKD (FIDELIO-DKD/FIGARO). The effect size is comparable to other kidney-protective drugs; hyperkalemia was more frequent but serious events were rare. Note the population skewed male with advanced CKD and severe albuminuria, with few Black participants, which limits generalizability.

Editorial — added August 6, 2026. FIND-CKD appeared online-first in this issue; its companion editorial (Toto, "Mineralocorticoid Receptor Antagonism — FINDing Another Benefit") published with the August 6 print issue. Toto frames finerenone as a potential foundational add-on in albuminuric CKD, layered onto a RAS inhibitor with or without an SGLT2 inhibitor — benefit was consistent across subgroups stratified by baseline SGLT2i use. Three points sharpen the trial:

• The magnitude is confirmatory, not novel. The −0.7 mL/min/1.73 m²/yr slope difference is identical to FIDELIO-DKD, and the Kaplan–Meier curves for the composite kidney–CV outcome separated at ~24 months, just as in FIDELIO-DKD. Composite risk was 23% lower with finerenone.

• The early eGFR dip is reversible — do not stop the drug for it. Finerenone caused an initial sharp eGFR decline, but mean eGFR rose again between the end-of-treatment visit and follow-up 4 weeks later. Toto states the short-term decline "should not prompt immediate discontinuation." This is the most practice-relevant line in the editorial.

• Some benefit may be blood-pressure–mediated: reductions in UACR and in systolic and diastolic BP were both greater with finerenone.

Limits Toto stresses: only ~2% of participants were Black and most were men (Asian or White); every participant had albuminuria, so the effect in non-albuminuric CKD is unknown. In the eGFR ≥60 subgroup the point estimate favored finerenone but was not significant — which he reads as a hint to start earlier, not as absence of effect. Hyperkalemia rarely caused hospitalization or discontinuation, and there were no hyperkalemia deaths.

Pulmonary & Critical CareSOHO · RCTHigh yield · IM

High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure

Population: 1,110 ICU adults with acute hypoxemic respiratory failure (Pao₂:Fio₂ ≤200, RR >25, pulmonary infiltrates); ~88% pneumonia. Excluded: hypercapnia (Paco₂ >45), COPD/chronic lung disease on home support, cardiogenic edema, shock, GCS <12, immediate intubation need, DNI.
Intervention: High-flow nasal oxygen (≥50 L/min, heated/humidified) for ≥48 h.
Comparison: Standard oxygen via non-rebreather mask (≥10 L/min).
Outcome: 28-day mortality: 14.6% vs 14.6% (difference −0.05 pts; 95% CI −4.2 to 4.1; P=0.98). Intubation by day 28: 42.4% vs 48.4% (difference −5.9 pts; 95% CI −11.8 to −0.08).

Clinical takeaway. High-flow nasal oxygen did not reduce 28-day mortality versus standard oxygen in acute hypoxemic respiratory failure, although intubation was less frequent. The editorial reframes high-flow oxygen as a tool that alters the respiratory-support pathway and patient comfort — and helps avoid intubation — rather than a mortality-reducing therapy, noting the trial was powered for a large mortality difference and the event rate ran lower than expected. Early high-flow oxygen in appropriate patients remains reasonable, with vigilance for deterioration.

Review · Clinical Practice

Childhood Vaccine Hesitancy · Preventive Medicine

Lower yield · IM/ID · pediatric framing

Key learning point. The clinician is the single most trusted influence on parents' vaccine decisions, and a strong, confident presumptive recommendation ("Sarah is due for three vaccines today") drives higher uptake than an open-ended, participatory opener ("What do you want to do about vaccines?") — supported by observational data and a randomized trial. When concerns surface, pair it with respectful, empathy-based dialogue and motivational interviewing; facts alone are usually insufficient.

Teaching Case · Clinical Problem-Solving

The Unusual Suspects · Hepatology / Infectious Disease

High yield · IM/ID

Key learning point. Two diagnoses can coexist, and acute liver injury demands a broad differential. A man with MSSA mitral-valve endocarditis (Osler nodes, Janeway lesion, splinter hemorrhages, septic emboli) had transaminases that only partially improved with antibiotics; rising aminotransferases with positive ANA and anti–smooth-muscle antibody and elevated IgG prompted a biopsy that revealed autoimmune hepatitis — unmasked by the acute infection and by inadvertent reduction/withdrawal of budesonide. Histologic clues: interface hepatitis and portal plasma cells.

Also in this issue (not randomized, so not summarized as trials): ASCERTAIN-V — a single-arm phase 1–2 study of all-oral decitabine–cedazuridine + venetoclax in newly diagnosed AML (complete response 47%). Plus a Brief Report (CAR T-cell desensitization before kidney transplantation) and a gene-therapy safety report (AAV integration and a neuroepithelial tumor).

Summaries are original paraphrases prepared for educational use; figures are drawn from the published full text. Read the full articles at NEJM.org (subscription required). Trials this week: CHAMPION-AF (NCT04394546), FIND-CKD (NCT05047263), SOHO (NCT04468126). Citations: N Engl J Med 2026;394 (Vol. 394, No. 21). Updated August 6, 2026 to add the FIND-CKD companion editorial (10.1056/NEJMe2608321), which published with the August 6, 2026 print issue (Vol. 395, No. 6).